A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2013 by Ohio State University Comprehensive Cancer Center
Sponsor:
Collaborators:
Celgene Corporation
Novartis
Information provided by (Responsible Party):
Kristie Blum, Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01460940
First received: October 14, 2011
Last updated: July 15, 2013
Last verified: July 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)